ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SAL0137

A development code. Also written as “SAL0137 Dose 1”, “SAL0137 Dose 2” and “SAL0137 Dose 3”.

Its studies are mostly in Atherosclerosis, led by Shenzhen Salubris Pharmaceuticals.

Furthest: phase 2, since Jul 22, 20261 company-led study, 1 open or runningNext primary completion: Dec 12, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Salubris Pharmaceuticals11 open or runningphase 2since Jul 22, 2026Jul 22, 2026Dec 12, 2026phase 2 · NCT07729475

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 22, 2026First study: phase 2 study in AtherosclerosisFirst studyNCT07729475 · 120 planned · China

Ahead

  1. Dec 12, 2026Primary completion: phase 2 study in AtherosclerosisNCT07729475

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07729475Atherosclerosis · China2Not yet recruitingDec 12, 2026120

How it is read

Names in the registry

  • “SAL0137 Dose 1”, 1 entry
  • “SAL0137 Dose 2”, 1 entry
  • “SAL0137 Dose 3”, 1 entry

Codes read as this program: SAL0137.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.